1-20 of 31
Huiling Pei
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Clinical Trials & Observations
Ashraf Z Badros, Laahn Foster, Larry D. Anderson, Jr., Chakra P. Chaulagain, Erin M Pettijohn, Andrew J Cowan, Caitlin L. Costello, Sarah Larson, Douglas W Sborov, Kenneth H Shain, Rebecca Silbermann, Nina Shah, Alfred Chung, Maria Krevvata, Huiling Pei, Sharmila Patel, Vipin Khare, Annelore Cortoos, Robin Carson, Thomas Lin, Peter M Voorhees
Journal: Blood
Blood blood.2024025746.
https://doi.org/10.1182/blood.2024025746
Published: 2024
Includes: Supplemental data
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Thierry Facon, Shaji K Kumar, Katja Weisel, Saad Usmani, Philippe Moreau, Torben Plesner, Robert Z. Orlowski, Nizar Jacques Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Robin Carson, Fredrik Borgsten, Hartmut Goldschmidt
Journal: Blood
Blood (2022) 140 (Supplement 1): 10133–10136.
https://doi.org/10.1182/blood-2022-163555
Published: 2022
Journal Articles

Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age

Brian G.M. Durie, Annette Lam, Mai Ngo, Huiling Pei, Eric M. Ammann
Journal: Blood
Blood (2022) 140 (Supplement 1): 10009–10010.
https://doi.org/10.1182/blood-2022-165591
Published: 2022
Journal Articles

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Maria-Victoria Mateos, Jesús San-Miguel, Michele Cavo, Joan Bladé Creixenti, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ludek Pour, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung-Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Meletios A. Dimopoulos
Journal: Blood
Blood (2022) 140 (Supplement 1): 10157–10159.
https://doi.org/10.1182/blood-2022-163347
Published: 2022
Journal Articles

An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne A. Efebera, Brandi Reeves, Tanya M. Wildes, Sarah A. Holstein, Larry D. Anderson, Jr., Ashraf Z. Badros, Leyla O. Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 10154–10156.
https://doi.org/10.1182/blood-2022-162473
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Ajai Chari, Jonathan L. Kaufman, Jacob P Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 7278–7281.
https://doi.org/10.1182/blood-2022-162339
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Shaji K Kumar, Philippe Moreau, Nizar Jacques Bahlis, Thierry Facon, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Saad Usmani
Journal: Blood
Blood (2022) 140 (Supplement 1): 10150–10153.
https://doi.org/10.1182/blood-2022-163335
Published: 2022
Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Natalie Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob P Laubach, Timothy Martin Schmidt, Douglas W Sborov, Eva Medvedova, Brandi Reeves, Binod Dhakal, Cesar Rodriguez, Saurabh Chhabra, Ajai Chari, Susan Bal, Larry D. Anderson, Jr., Bhagirathbhai Dholaria, Nitya Nathwani, Parameswaran Hari, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Ken H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Smith Giri, Luciano J. Costa, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 10144–10147.
https://doi.org/10.1182/blood-2022-160451
Published: 2022
Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Rebecca Silbermann, Jacob Laubach, Jonathan L. Kaufman, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J. Costa, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Katharine S. Gries, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 1146–1149.
https://doi.org/10.1182/blood-2022-162313
Published: 2022
Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Aurore Perrot, Thierry Facon, Torben Plesner, Saad Usmani, Shaji K Kumar, Nizar Jacques Bahlis, Cyrille Hulin, Robert Z. Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Huiling Pei, Niodita Gupta, Shuchita Kaila, Kathryn Matt, Katharine S. Gries, Robin Carson, Fredrik Borgsten, Katja Weisel
Journal: Blood
Blood (2022) 140 (Supplement 1): 1142–1145.
https://doi.org/10.1182/blood-2022-165524
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Philippe Moreau, Thierry Facon, Saad Usmani, Nizar Jacques Bahlis, Noopur Raje, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 7297–7300.
https://doi.org/10.1182/blood-2022-163494
Published: 2022
Journal Articles

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Clinical Trials & Observations
Jesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, Shaji Kumar, Meletios A. Dimopoulos, Thierry Facon, María-Victoria Mateos, Cyrille Touzeau, Andrzej Jakubowiak, Saad Z. Usmani, Gordon Cook, Michele Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Mia Qi, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, Rachel Kobos, Ming Qi, Nizar J. Bahlis
Journal: Blood
Blood (2022) 139 (4): 492–501.
https://doi.org/10.1182/blood.2020010439
Published: 2022
Includes: Supplemental data
Journal Articles

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

Saurabh Chhabra, Natalie S. Callander, Luciano J. Costa, Jonathan L. Kaufman, Jacob P. Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Bhagirathbhai Dholaria, Huiling Pei, Annelore Cortoos, Sharmila Patel, J Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhees
Journal: Blood
Blood (2021) 138 (Supplement 1): 2852.
https://doi.org/10.1182/blood-2021-149028
Published: 2021
Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin

Larry D. Anderson, Jr., Jonathan L. Kaufman, Jacob P. Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Luciano J. Costa, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, J Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Peter M. Voorhees, Paul G. Richardson
Journal: Blood
Blood (2021) 138 (Supplement 1): 2723.
https://doi.org/10.1182/blood-2021-148533
Published: 2021
Journal Articles

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose

Saad Z. Usmani, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael E. O'Dwyer, Aurore Perrot, Chris P. Venner, Katja Weisel, Joseph R. Mace, Noopur S. Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Rian Van Rampelbergh, Brenda Tromp, Maria Delioukina, Thierry Facon
Journal: Blood
Blood (2021) 138 (Supplement 1): 1646.
https://doi.org/10.1182/blood-2021-146940
Published: 2021
Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

Jacob P. Laubach, Jonathan L. Kaufman, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Luciano J. Costa, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Yvonne A. Efebera, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, J Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhees
Journal: Blood
Blood (2021) 138 (Supplement 1): 79.
https://doi.org/10.1182/blood-2021-149024
Published: 2021
Journal Articles

Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda

Ashutosh D. Wechalekar, MD, Giovanni Palladini, MD PhD, Giampaolo Merlini, MD, Raymond L. Comenzo, MD, Arnaud Jaccard, MD PhD, NamPhuong Tran, MD, Huiling Pei, PhD, Sandra Y. Vasey, MSc, Brenda Tromp, MSc, Brendan M. Weiss, MD, Jessica Vermeulen, MD PhD, Efstathios Kastritis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–7.
https://doi.org/10.1182/blood-2020-140514
Published: 2020
Journal Articles

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Jesus F. San-Miguel, MD PhD, Herve Avet-Loiseau, Bruno Paiva, PhD, Shaji K. Kumar, MD, Meletios A. Dimopoulos, MD, Thierry Facon, MD, Maria-Victoria Mateos, MD PhD, Cyrille Touzeau, Andrzej Jakubowiak, MD PhD, Saad Z. Usmani, MDMBBS,MBA, Gordon Cook, MD, Michele Cavo, Hang Quach, MDFRACP,FRCPA,MBBS, Jon Ukropec, PhD, Priya Ramaswami, Huiling Pei, PhD, Steven Sun, Jianping Wang, Maria Krevvata, PhD, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, MD, Rachel Kobos, MD, Ming Qi, MD PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–20.
https://doi.org/10.1182/blood-2020-134928
Published: 2020
Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Jonathan L. Kaufman, MD, Jacob P. Laubach, Douglas Sborov, MD MS, Brandi Reeves, MD, Cesar Rodriguez, MD, Ajai Chari, Rebecca W. Silbermann, MD, Luciano J. Costa, MD PhD, Larry D. Anderson, Jr., MD PhD, Nitya Nathwani, MD, Nina Shah, MD, Yvonne A. Efebera, MD MPH, Sara A. Holstein, MDPhD, Caitlin Costello, Andrzej Jakubowiak, MD PhD, Tanya M. Wildes, MD MSCI, Robert Z. Orlowski, MDPhD, Kenneth H. Shain, MD PhD, Andrew J. Cowan, Yana Lutska, PharmD, Padma Bobba, Huiling Pei, PhD, Jon Ukropec, PhD, Jessica Vermeulen, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD, Peter M. Voorhees
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-137109
Published: 2020
Journal Articles

Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM)

Niels W. C. J. van de Donk, Sonja Zweegman, MDPhD, Jesus F. San-Miguel, MD PhD, Meletios A Dimopoulos, Michele Cavo, Kenshi Suzuki, MD PhD, Cyrille Touzeau, Saad Z. Usmani, MDMBBS,MBA, Aurore Perrot, Huiling Pei, PhD, Anupa Kudva, MD, Rian Van Rampelbergh, Jon Ukropec, PhD, Kevin Leary, Robin Carson, MD BA, Ming Qi, MD PhD, Ajai Chari
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-134923
Published: 2020